The fight against opioid addiction is gaining momentum, with the Opioid Use Disorder Treatment Market projected to reach a significant USD 8.4 billion by 2033. This marks a substantial rise from the current market valuation of USD 3.07 billion in 2023. This growth is fueled by a CAGR (Compound Annual Growth Rate) of a promising 10.5% over the next decade.
This increases their customer pool which directly aids in market expansion of Opioid use disorder treatment. Growing awareness through television advertisements, newspapers, information brochures, and other media is proving to be very effective in impeding the opioid abuse crisis to a certain extent.
Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16561
Various organizations are participating with other organizations which are leading to the industry’s expansion. For example, in March 2016, GlaxoSmithKline collaborated with 2morrow Inc., developer of the SmartQuit app to supply patches to smokers having the app plan. Similarly, In August 2013, the company agreed to distribute its Buprenorphine HCl and Naloxone HCl Dihydrate Sublingual Tablets (CIII), a generic version of Suboxone with Amneal Pharmaceuticals LLC, to the addiction treatment centers. This will benefit the market in the long term.
On the other hand, the addiction crisis over the past decade has driven the need to invest in integrated research and development activities that focus on addiction treatment and the recovery process. Even though the number of research activities about issues related to Opioid use disorder has increased at an impressive pace, stakeholders operating in the current treatment market landscape are progressively finding new methods to apply these findings to real-world care delivery. This is expected to fuel the market’s growth in the forthcoming period.
Some of the other factors propelling growth in this market include the rising prevalence of diseases that cause chronic pain, such as cancer, lower back pain arthritis, fibromyalgia, and postsurgical pain, interest toward extended-release formulations from the immediate release of opioids, and increasing focus on the abuse-deterrent formulation (ADF) by generic manufacturers.
In addition, in countries such as the United Kingdom, the National Health Service runs various public and privately funded programs for the treatment of Opioid use disorder. Moreover, several companies adopt the strategies of merger and acquisition to bolster their market presence in new geographies or add new products and services or both to existing platforms, which helps the industry to grow. For example, in December 2015, Acadia Healthcare acquired Priory Group, a leading provider of behavioral care services in the United Kingdom. This acquisition was intended to expand Acadia Healthcare’s capacity and geographic presence in the United Kingdom which would help in growing the overall market of Opioid use disorder treatment.
However, the rising expenditure required for the diverse treatment processes is challenging market growth. Several market players make huge investments in manufacturing new and medically advanced treatment procedures to boost the recovery process, and in return, it increases treatment costs which then hampers the growth of the industry.
Opioid Use Disorder Treatment Market Key Takeaways
- North America is expected to dominate the industry while reaching a market share of around 48% by the end of the forecast period.
- The market in East Asia is projected to reflect the fastest CAGR of 8.8% during the projected timeline.
- By drug class, Buprenorphine is projected to account for 81.4% market share by the end of the forecast period.
- Hospitals are expected to dominate the market by distribution channel, with a market share of 35% by 2033.
“Rising collaborations and mergers between companies, increasing research and development activities and adoption of technological advanced techniques for treating Opioid disorder will drive the industry’s growth,” comments an FMI analyst
Opioid Use Disorder Treatment Market Competitive Landscape
The Opioid use disorder treatment Market is competitive and consists of several major players. Major players are creating novel delivery systems for the treatment of opioid use disorder. This is expected to propel the Opioid use disorder treatment market. The major players in the market are Trevena, Opiate Pharmaceutical, Aphios, Kyowa kirin, Gamida-Cell, Novartis, Titan Pharmaceuticals, Inc., Hikma Pharmaceuticals, MediciNova, Alkermes, Inc., BioDelivery Sciences International, Inc.
Some recent developments in the Opioid Use Disorder Treatment Market are:
- In January 2022, Trevena, Inc. declared that China’s National Medical Products Administration (NMPA) has accepted the submission of a New Drug Application (NDA) for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the FDA for use in adults for managing acute pain severe enough to require an intravenous opioid analgesic.
- In October 2021, Esteve Pharmaceuticals received authorization from the United States Food and Drug Administration (FDA) for SEGLENTIS (celecoxib and tramadol hydrochloride) for the management of acute pain in adults that is extreme enough to require an opioid analgesic.
- In January 2020, Titan Pharmaceuticals, Inc. made a revelation that they had entered into an agreement with AllianceRx Walgreens Prime for the expansion of accessibility of patients for Titan’s opioid use disorder implant branded as “Probuphine implant”.
Request Discount
https://www.futuremarketinsights.com/request-discount/rep-gb-16561
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global Opioid use disorder treatment market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.
To understand opportunities in the Opioid use disorder treatment market, the market is segmented based on drug class (Romiplostim, Omidubicel, Nalmefene, buprenorphine, Methadone, Naltrexone) By route of administration (Oral, Parenteral), by distribution channel (Hospital pharmacies, retail pharmacies, online pharmacies) by region (North America, Europe, Latin America, East Asia, South Asia, Oceania, Middle East and Africa)
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
Key Segments Profiled in the Opioid Use Disorder Treatment Market Survey
By Drug Type:
- Romiplostim
- Omidubicel
- Nalmefene
- Buprenorphine
- Methadone
- Naltrexone
By Route of Administration:
- Oral
- Parenteral
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
